Colleen Moretti

Eating a plant-based diet has been associated with sustained MRD negativity for patients with multiple myeloma.

Breast cancer treatment can disrupt patients’ quality and quantity of sleep, leaving them fatigued and restless during the day.

An expert discusses the impact on patients and families lacking equal access to counseling and testing.

Although the pandemic prevented Branwyn Lee's family from being with her during cancer treatment, she never felt alone on her journey.

Recent results highlight that men with the disease have not lived as long as female patients have during the past three decades.

PARP inhibitors, primarily used to treat BRCA-mutated disease, may have efficacy potential in triple negative breast cancer.

Patients and their caregivers may benefit from community support and education following an MPN diagnosis

Patients with MPNs should consult with their treating physician to individualize a healthy, nutritious diet to help ease symptoms.

Watch Dr. Kevin Kalisnky, from Winship Cancer Institute of Emory University, discuss treatment for triple-negative disease during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Watch Dr. William J. Gradishar, from Northwestern University, discuss the management of hormone receptor-positive disease during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Triplet therapy demonstrates improved remission and survival rates, with manageable side effects for patients who are ineligible for transplant.

Cabometyx plus Tecentriq failed to improve progression-free survival in patients with kidney cancer.

Patients with HER2-positive metastatic breast cancer treated with the novel antibody drug conjugate ARX788 conferred a significant survival benefit compared with those treated with a control.

Keytruda plus chemotherapy before surgery and as single agent after improved outcomes for patients with resectable non-small cell lung cancer.

Regarding overall survival, allogeneic HCT did not have a benefit over consolidation chemotherapy in patients with intermediate-risk disease.

Hodgkin lymphoma survivors should avoid associated risk factors of developing colorectal cancer such as smoking, alcohol usage and being overweight.

Gefitinib plus chemotherapy could be considered a first-line treatment option for patients with EGFR-mutated NSCLC with brain metastases.

Latino patients with acute lymphoblastic leukemia and a high level of serum creatine may have an almost six-fold increased risk of neurotoxicity.

One of the trials investigating Keytruda has been discontinued because the drug did not significantly improve outcomes in patients with prostate cancer.

Patients who experience cardiovascular side effects, such as shortness of breath or chest pain, after cancer treatment should speak with their health care provider about further heart testing.

The first patient has been enrolled in a clinical trial evaluating IMNN-001, an immunotherapy, combined with Avastin for the treatment of advanced ovarian cancer.

Cancer survivors who are experiencing side effects from treatment, such as chronic fatigue, may benefit from a healthier diet.

The designation is based on study findings demonstrating that the cancer vaccine-Keytruda combination reduces the risk of recurrence or death by 44% in the adjuvant setting for patients with melanoma.

Important data may encourage gender-specific treatment making decisions for patients with bladder cancer.

Patients with cancer should keep a healthy heart during cancer treatment by exercising regularly and eating healthy, an expert emphasized.

The combination demonstrated survival benefit in patients with metastatic hormone-sensitive prostate cancer, regardless of risk or volume of disease.

Carvykti and other drugs prove that there are still options for patients whose myeloma got worse on prior therapies.

The hold has been placed due to visual side effects in a number of patients with solid tumors.

Patients who are financially struggling due to job loss after a cancer diagnosis may benefit from multidisciplinary back-to-work programs and financial counseling, according to an expert.

Orserdu demonstrated improved outcomes and quality of life for certain patients with metastatic breast cancer.